Welcome to our dedicated page for Actuate Therapeutics SEC filings (Ticker: ACTU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elraglusib鈥檚 journey from lab bench to clinic means Actuate Therapeutics鈥� SEC disclosures are packed with dense data on GSK-3尾 science, trial cohorts, and cash runway projections鈥攄etails critical for biotech investors yet hard to digest quickly.
Problem: Finding the latest dose-limiting toxicity update inside a 300-page 10-K or spotting a sudden insider stock sale before a Phase 2 read-out can take hours. Solution: Stock Titan鈥檚 AI-powered platform turns every Actuate Therapeutics filing into an executive-level brief. Our engine highlights clinical-trial milestones, R&D spend, and partnership terms, then links them to market-moving events.
Access every document the moment it hits EDGAR: 10-K annual reports, 10-Q quarterly earnings, 8-K material events, S-1 fundraising prospectuses, and real-time Form 4 insider trades. Investors searching for 鈥淎ctuate Therapeutics insider trading Form 4 transactions鈥� or 鈥淎ctuate Therapeutics quarterly earnings report 10-Q filing鈥� land here because we answer those questions directly. Want the proxy statement executive compensation breakdown? It鈥檚 parsed and summarised. Need 鈥淎ctuate Therapeutics 8-K material events explained鈥�? Our AI does that, too.
Practical use cases include:
- Monitoring 鈥淎ctuate Therapeutics Form 4 insider transactions real-time鈥� to gauge management sentiment.
- Reviewing 鈥淎ctuate Therapeutics earnings report filing analysis鈥� to compare cash burn across quarters.
- Downloading an 鈥淎ctuate Therapeutics annual report 10-K simplified鈥� to understand pipeline risk factors without legalese.
Actuate Therapeutics, Inc. (ACTU) prospectus supplement describes an offering of common stock and related securities and discloses financing, dilution and operational risks. The document states lock-up agreements restricting insider sales for 90 days and an underwriting-related 75-day restriction. It lists share counts reserved or issuable as of June 30, 2025 and September 5, 2025, including restricted stock units, outstanding options (1,774,477 as of June 30, 2025), warrants exercisable for 922,096 shares at a weighted average exercise price of $7.87, and multiple amounts reserved under a Committed Equity Facility with B. Riley (3,364,407 as of September 5, 2025; 3,647,945 as of June 30, 2025). The supplement highlights material risks: substantial doubt about the company鈥檚 ability to continue as a going concern, the need for additional capital, potential dilution to existing holders, and clinical, regulatory and market risks related to elraglusib and other product candidates. The prospectus incorporates prior SEC reports and exhibits for further detail.
Actuate Therapeutics, Inc. (ACTU) filed a Form S-3 shelf registration prospectus that describes the types of securities it may offer, including common stock, debt securities, warrants and units, and summarizes the general terms and procedures that will govern future offerings. The document repeatedly states that specific terms鈥攕uch as aggregate offering amounts, prices, interest or dividend rates, maturities, conversion or exercise mechanics, redemption and default provisions, trustee rights, and fees鈥攚ill be provided in an applicable prospectus supplement or in exhibits to the registration statement. The prospectus also references incorporated reports and exhibits for further detail and includes officer and director signatures attesting to the filing.
Actuate Therapeutics (NASDAQ:ACTU) entered a $4.7 million private placement with institutional and accredited investors, selling 666,497 common shares at $7.00 and issuing 666,497 cash-only warrants at the same price. Warrants are immediately exercisable and expire 20 days after an FDA milestone (Breakthrough Therapy designation or Phase 2/3 registration pathway feedback), potentially providing another $4.7 million.
Closing is expected by June 30 2025; proceeds earmarked for working capital. Bios 2024 Co-Invest will hold ~49.9 % beneficial ownership post-deal. A Registration Rights Agreement requires ACTU to file a resale shelf by August 9 2025 and meet strict effectiveness deadlines, with liquidated damages for failure.
- Item 1.01: Securities Purchase & Warrants
- Item 3.02: Unregistered sales under Reg D
- Going-concern risk remains despite new funding.
FAQ
What is the current stock price of Actuate Therapeutics (ACTU)?
What is the market cap of Actuate Therapeutics (ACTU)?
